Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy? The Motley Fool
Covered in this story
Analyst targets on AbbVie
- RBC Capital Markets: at $289 · target $330 by Nov 2027 · Outperform via Investing.com
- Wells Fargo: at $289 · target $340 by Nov 2027 · Overweight via Investing.com
- UBS: at $276 · target $275 by Oct 2027 · Neutral via GuruFocus
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 34 stories mentioning AbbVie, the earliest published 6 Jan 2013.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.